NETRIS Pharma Announces First Patient Dosed in Phase Ib/II

NETRIS Pharma Announces First Patient Dosed in Phase Ib/II GYNet Study of First-in-Class NP137 in combination with chemotherapy and/or KEYTRUDA®   December 31, 2020 LYON, France – NETRIS Pharma, a clinical-stage biopharmaceutical company developing therapeutics based...

NETRIS Pharma successfully completes a €16.1m Series A

December 23rd, 2020 – Geneva – Switzerland and Lyon – France NETRIS Pharma, a clinical-stage biopharmaceutical company developing next generation molecules targeting cancer, today announced the closing of a €16.1m Series A financing and the reinforcement of its Board...